Rui Shi's research while affiliated with Chinese Academy of Sciences and other places
What is this page?
This page lists the scientific contributions of an author, who either does not have a ResearchGate profile, or has not yet added these contributions to their profile.
It was automatically created by ResearchGate to create a record of this author's body of work. We create such pages to advance our goal of creating and maintaining the most comprehensive scientific repository possible. In doing so, we process publicly available (personal) data relating to the author as a member of the scientific community.
If you're a ResearchGate member, you can follow this page to keep up with this author's work.
If you are this author, and you don't want us to display this page anymore, please let us know.
It was automatically created by ResearchGate to create a record of this author's body of work. We create such pages to advance our goal of creating and maintaining the most comprehensive scientific repository possible. In doing so, we process publicly available (personal) data relating to the author as a member of the scientific community.
If you're a ResearchGate member, you can follow this page to keep up with this author's work.
If you are this author, and you don't want us to display this page anymore, please let us know.
Publications (17)
Background
Increasing severe morbidity and mortality by simultaneous or sequential infections with SARS-CoV-2 and influenza A viruses (IAV), especially in the elderly and obese patients, highlight the urgency of developing a combination vaccine against COVID-19 and influenza.
Methods
Self-assembling SARS-CoV-2 RBD-trimer and Influenza H1N1 HA1-tri...
Since the palivizumab for respiratory syncytial virus was approved in 1998, therapeutic antibodies against infectious diseases have been widely used in clinical treatment. Since the outbreak of COVID-19, plenty of neutralizing antibodies were developed and transferred into clinical trials, holding enormous promise for the treatment of COVID-19 unde...
Since the first report on November 24, 2021, the Omicron SARS-CoV-2 variant is now overwhelmingly spreading across the world. Two SARS-CoV-2 inactivated vaccines (IAVs), one recombinant protein subunit vaccine (PRV), and one adenovirus-vectored vaccine (AdV) have been widely administrated in many countries including China to pursue herd immunity. H...
The neutralizing antibody is a potential therapeutic for the ongoing COVID-19 pandemic. As an antiviral agent, numerous mAbs recognize the epitopes that overlap with ACE2-binding sites in the SARS-CoV-2-RBD. Some studies have shown that residual changes on the spike protein can significantly decrease the efficiency of neutralizing antibodies. To ad...
The successive emergences and accelerating spread of novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) lineages and evolved resistance to some ongoing clinical therapeutics increase the risks associated with the coronavirus disease 2019 (COVID-19) pandemic. An urgent intervention for broadly effective therapies to limit the morbidi...
SARS-CoV-2 variants could induce immune escape by mutations on the receptor-binding domain (RBD) and N-terminal domain (NTD). Here we report the humoral immune response to circulating SARS-CoV-2 variants, such as 501Y.V2 (B.1.351), of the plasma and neutralizing antibodies (NAbs) elicited by CoronaVac (inactivated vaccine), ZF2001 (RBD-subunit vacc...
In order to meet the domestic urgent needs of evaluating the immunogenicity of vaccines and the potency testing of therapeutic antibody products against coronavirus disease 2019 (COVID-19), the first Chinese national standards for SARS-CoV-2 neutralizing antibody were established. The potency and stability of the candidate standards were determined...
COVID-19 has evolved into a global pandemic. Early and rapid detection is crucial to control of the SARS-CoV-2 transmission. While representing the gold standard for early diagnosis, nucleic acid tests for SARS-CoV-2 are often complicated and time-consuming. Serological rapid antibody tests are characterized by high rates of false-negative diagnose...
An outbreak of the coronavirus disease 2019 (COVID-19)1–3, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)4 spread globally. Countermeasures are needed to treat and prevent further dissemination of the virus. In this study, we report the isolation of 2 specific human monoclonal antibodies (MAbs) from a convalescent COVID-...
The recently emerged coronavirus disease COVID-19 has now evolved into a global pandemic. Early detection is crucial for its effective control. Nucleic acid testing for viral pathogen and serological testing for host antibodies are playing important roles in current COVID-19 diagnosis. However, while nucleic acid testing is complicated, facility-re...
Rift Valley fever virus (RVFV) is a mosquito-borne pathogen that causes substantial morbidity and mortality in livestock and humans. To date, there are no licensed human vaccines or therapeutics available. Here, we report the isolation of monoclonal antibodies from a convalescent patient, targeting the RVFV envelope proteins Gn and Gc. The Gn-speci...
Programmed cell death 1 (PD-1)/PD-1 ligand-1 (PD-L1)-blocking monoclonal antibodies (mAbs) have taken center stage for tumor immune checkpoint therapy. Identification of the “hotspots” on PD-1 for mAbs will help to develop next-generation oral deliverable agents with long-lasting efficacy. Here, we identified two PD-1-targeting mAbs, GY-5 and GY-14...
Citations
... More manufacturers can join this race, as many different co-formulated vaccines are still under preclinical development [14][15][16][17][18], including live-attenuated influenza virus (LAIV) vector-based vaccines [19][20][21]. Among the latter, the intranasal candidate developed by Beijing Wantai Biological Pharmacy Enterprise achieved poor immunogenicity in a phase 1/2 clinical trial [22]. ...
... Over the past two years, seven groups of neutralizing antibody therapies were authorized for emergency use by the FDA or EMA, including Casirivimab/Imdevimab, Bamlanivimab (withdrawn due to lack of efficiency), Bamlanivimab/Etesevimab, Sotrovimab, Regdanvimab, Tixagevimab/Cilgavimab, and Bebtelovimab. Another group named Amubarvimab/ Romlusevimab (BRII 196/198) was approved for marketing in China on December 8, 2021 [1][2][3]. In addition, several other neutralizing antibody-based drugs against COVID-19 have reached phase II/ III clinical trials and are expected to play an important role in the prevention and treatment of COVID-19 disease. ...
... Third, a national COVID-19 vaccination policy should be implemented to ensure full coverage of vaccination. COVID-19 vaccination is one of the most effective methods to prevent infection, especially severe infection [14,15] , which is important in taking precautions against COVID-19-induced mental health problems. Inappropriate and invalid vaccination publicity can increase stress levels related to COVID-19 vaccination. ...
![[object Object]](https://i1.rgstatic.net/ii/profile.image/591726406279168-1518089977073_Q64/Qingrui-Huang.jpg)
... [11][12][13] Besides the homologous boosting, heterologous booster strategy has also attracted great concerns, and multiple clinical trials and cohort studies have shown that the immune response elicited by heterologous prime-booster vaccination was significantly greater than that induced by homologous counterparts. [14][15][16][17][18][19][20][21] Currently, several clinical trials have been conducted to evaluate the safety, immunogenicity and efficacy of a heterologous booster dose of recombinant subunit vaccines, such as V-01 (NCT05096832), ZF2001 ...
... recognizing epitopes outside the RBM locus, and show some e cacy against the Omicron variant. 46,47 Also, 5A6, CoVA2-04, and CoVA2-39 inhibited interactions between ACE2 and Spike Wuhan-Hu-1/Delta strains, but this was not the case for in Spike o1 or RBD o1 (Fig. 3bii). For ACE2 inhibition assays, neutralizers that bind RBD often exhibit >40% inhibition. ...
![[object Object]](https://i1.rgstatic.net/ii/profile.image/1056233041702914-1628836989697_Q64/Pulan-Liu.jpg)
... Neutralizing antibody JS026 has excellent neutralizing activity against SARS-CoV-2. In addition, the combination of JS026 and JS016 has synergistic effects, as their binding sites are complementary to the virus 40,41 . Phase Ⅰ/Ⅱ/Ⅲ clinical trials of JS016 and JS026 have been approved in China. ...
... Clinical trials have shown that ACE2 receptor activation has the potential to alleviate pulmonary injury, vascular damage, and lung fibrosis, which can synergistically relieve symptoms of COVID-19 [57]. In a study by Du et al. [58], an ACE2-blocking mAb was isolated and humanized. The mAb was found to possess robust inhibitory activity against both SARS-CoV and circulating global strains of SARS-CoV-2 without any significant changes in blood pressure, hematology, or toxicology parameters in cynomolgus monkeys. ...
... Although we did observe a modest effect on early humoral immunity to the Omicron variant BF.7. This could be attributed to the antibody profile elicited by the booster shots, which appears to be more focused on the original strain [41]. In a study conducted by Bessen et al. [35], it was observed that low CD4 + T-cell counts did not impede the cellular immune response in people living with HIV (PLWH). ...
![[object Object]](https://i1.rgstatic.net/ii/profile.image/1026925556412417-1621849540449_Q64/Yunlong-Cao.jpg)
![[object Object]](https://i1.rgstatic.net/ii/profile.image/1096492840419334-1638435673984_Q64/Weijin-Huang.jpg)
... Companies should design, develop, and produce vaccines based on the concept of risk management, scientifically and reasonably set quality control projects and acceptable standards, and establish simple and accurate testing methods that meet the expected purposes. Regulatory authorities should promote the uniformity of quality control standards and the application of standardized methods to provide a foundation for promoting the development of mRNA vaccines and developing safe and effective vaccines [28]. ...
![[object Object]](https://i1.rgstatic.net/ii/profile.image/1050508198424578-1627472080281_Q64/Jianhui-Nie-2.jpg)
... Furthermore, SARS-CoV-2 N protein is an extremely important candidate protein for the development of various diagnostic methods for novel coronavirus diseases [4]. At present, there are some reliable analytical methods for SARS-CoV-2 N protein such as chemiluminescence immunoassays [5], enzyme-linked immunosorbent assays (ELISAs) [6], lateral flow immunoassays (LFAs) [7] and biosensing immunoassays [8]. Biosensor can realize qualitative analysis and quantitative detection with its advantages of high sensitivity and strong specificity. ...
